KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) EBT (2017 - 2025)

Bionano Genomics' EBT history spans 7 years, with the latest figure at -$8.5 million for Q3 2025.

  • For Q3 2025, EBT rose 80.81% year-over-year to -$8.5 million; the TTM value through Sep 2025 reached -$38.6 million, up 71.61%, while the annual FY2024 figure was -$112.0 million, 51.82% up from the prior year.
  • EBT for Q3 2025 was -$8.5 million at Bionano Genomics, down from -$6.8 million in the prior quarter.
  • Across five years, EBT topped out at -$3.1 million in Q1 2025 and bottomed at -$112.5 million in Q3 2023.
  • The 5-year median for EBT is -$29.9 million (2022), against an average of -$30.1 million.
  • The largest annual shift saw EBT plummeted 254.07% in 2023 before it soared 90.16% in 2025.
  • A 5-year view of EBT shows it stood at -$28.7 million in 2021, then dropped by 28.4% to -$36.9 million in 2022, then fell by 19.13% to -$43.9 million in 2023, then soared by 54.19% to -$20.1 million in 2024, then skyrocketed by 57.82% to -$8.5 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's EBT are -$8.5 million (Q3 2025), -$6.8 million (Q2 2025), and -$3.1 million (Q1 2025).